|
In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion.
MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets.
In a separate but concurrent announcement, 4DMedical has secured firm commitments from select institutional investors for an AU$83 million single-tranche private placement. This additional capital will support the Company's growth strategy, particularly the expansion of CT:VQ™ in Europe.
CT:VQ™ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure.
Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ™ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT.
For large medical institutions, CT:VQ™ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity.
The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need.
"CE Mark certification for CT:VQ™ is a significant milestone that opens access to one of the world's largest and most sophisticated healthcare markets," said Andreas Fouras, Managing Director, CEO and Founder of 4DMedical. "Combined with FDA clearance, 4DMedical now has regulatory clearance to rapidly commercialise CT:VQ™ across both the U.S. and the EU.
"The clinical need for CT:VQ™ is universal. The limitations of nuclear VQ scanning—radiotracer constraints, limited access and operational complexity—exist across healthcare systems globally. Europe has the clinical expertise, imaging infrastructure and research leadership to play a major role in the adoption and evidence generation for this technology."
The CE Mark follows growing U.S. momentum for CT:VQ™, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ™ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe.
4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ™.
About CT:VQ™
CT:VQ™ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology®, CT:VQ™ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers.
About 4DMedical
4DMedical Limited (ASX:4DX) is a global medical technology company that creates and deploys the most advanced software-based cardiothoracic imaging technology—integrating both proprietary algorithms and artificial intelligence. 4DMedical's software platform delivers deep, quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease.
These insights help respiratory physicians, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical's solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions. Learn more at www.4dmedical.com.
Photo - https://mma.prnasia.com/media2/2944827/Lungs_Graphic_Cutouts_Color_BW.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2730645/5888947/4DMedical_Logo.jpg?p=medium600
In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion.
MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets.
In a separate but concurrent announcement, 4DMedical has secured firm commitments from select institutional investors for an AU$83 million single-tranche private placement. This additional capital will support the Company's growth strategy, particularly the expansion of CT:VQ™ in Europe.
CT:VQ™ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure.
Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ™ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT.
For large medical institutions, CT:VQ™ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity.
The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need.
"CE Mark certification for CT:VQ™ is a significant milestone that opens access to one of the world's largest and most sophisticated healthcare markets," said Andreas Fouras, Managing Director, CEO and Founder of 4DMedical. "Combined with FDA clearance, 4DMedical now has regulatory clearance to rapidly commercialise CT:VQ™ across both the U.S. and the EU.
"The clinical need for CT:VQ™ is universal. The limitations of nuclear VQ scanning—radiotracer constraints, limited access and operational complexity—exist across healthcare systems globally. Europe has the clinical expertise, imaging infrastructure and research leadership to play a major role in the adoption and evidence generation for this technology."
The CE Mark follows growing U.S. momentum for CT:VQ™, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ™ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe.
4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ™.
About CT:VQ™
CT:VQ™ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology®, CT:VQ™ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers.
About 4DMedical
4DMedical Limited (ASX:4DX) is a global medical technology company that creates and deploys the most advanced software-based cardiothoracic imaging technology—integrating both proprietary algorithms and artificial intelligence. 4DMedical's software platform delivers deep, quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease.
These insights help respiratory physicians, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical's solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions. Learn more at www.4dmedical.com.
Photo - https://mma.prnasia.com/media2/2944827/Lungs_Graphic_Cutouts_Color_BW.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2730645/5888947/4DMedical_Logo.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
|
Night City is set to come alive in a new location-based VR experience built for freedom, intensity, and unique shared moments.
MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- Zero Latency VR, the undisputed leader in immersive entertainment and the mastermind behind the world's largest true location-based free-roam VR network, has announced a new collaboration with CD PROJEKT RED to bring the award-winning universe of Cyberpunk 2077 into its warehouse-scale VR format.
 
You’ve played Night City. Now you live it. Zero Latency VR has teamed up with Cyberpunk 2077 to put you inside a fully immersive VR experience — only available at our locations. Be a mercenary. Build your crew. Become a legend. Coming soon.
Cyberpunk 2077 is an open-world, action-adventure role-playing game set in Night City, a dark future megalopolis obsessed with power, glamour, and body modification. Players take on the role of a cyber-enhanced mercenary named V, who faces the most powerful forces in the city in a fight for glory and survival. Created by the studio behind The Witcher series of games, Cyberpunk 2077 has reached a global audience since its launch in 2020, earning acclaim for its storytelling, gameplay, and the immersive nature of its open world.
This brand-new in-person experience, based on the world of Cyberpunk 2077, is built specifically for Zero Latency VR's untethered, free-roam technology. It will allow players to physically move together through a shared space, offering a new way to explore the world of Cyberpunk 2077. This will be a self-contained experience capturing the atmosphere and style of Night City beyond its original screen-based format, as seen in the original video game.
"Cyberpunk 2077 is one of the most richly imagined worlds in modern entertainment," said Tim Ruse, CEO of Zero Latency VR. "What makes this collaboration special is how naturally it aligns with what we do best. Zero Latency experiences are about freedom of movement and shared adrenaline, and Night City is a world that begs to be explored at a human scale. CD PROJEKT RED are experts in their craft, and we're looking forward to creating a new, unforgettable adventure."
Inspired by the world of Cyberpunk 2077, but not a direct translation of the video game, the experience will be developed specifically for Zero Latency VR's global network of venues, leveraging large-scale arenas, wireless headsets, and full-body movement to deliver a social, fully immersive VR adventure unlike anything currently available.
Additional details about the experience will be announced at a later date. The Cyberpunk 2077 immersive VR experience is set to launch at Zero Latency VR locations worldwide.
ABOUT ZERO LATENCY VR:
Zero Latency VR is the global pioneer in immersive entertainment, pushing the boundaries of what's possible in location-based experiences. As the largest free-roam VR network on the planet, with 150+ cutting-edge venues across 30 countries, Zero Latency is where thrill-seekers come to live out their wildest fantasies.
ABOUT CD PROJEKT RED:
CD PROJEKT RED is a video game development studio founded in 2002. Its flagship titles include the futuristic role-playing game Cyberpunk 2077 and its spy-thriller expansion Phantom Liberty, alongside The Witcher series of games including The Witcher 3: Wild Hunt and its two expansions. CD PROJEKT RED also created the award-winning Netflix anime series Cyberpunk: Edgerunners, set in the same universe as the game. CD PROJEKT RED is part of the CD PROJEKT Group. CD PROJEKT S.A. is listed on the Warsaw Stock Exchange (ISIN: PLOPTTC00011).
SOCIAL MEDIA LINKS:
Instagram and TikTok: @zerolatencyvr
LinkedIn: Zero Latency VR
Press Contact:
Luke Mitchell
PR & Communications Manager
+61 (0) 413614412
luke.mitchell@zerolatencyvr.com
Night City is set to come alive in a new location-based VR experience built for freedom, intensity, and unique shared moments.
MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- Zero Latency VR, the undisputed leader in immersive entertainment and the mastermind behind the world's largest true location-based free-roam VR network, has announced a new collaboration with CD PROJEKT RED to bring the award-winning universe of Cyberpunk 2077 into its warehouse-scale VR format.
 
You’ve played Night City. Now you live it. Zero Latency VR has teamed up with Cyberpunk 2077 to put you inside a fully immersive VR experience — only available at our locations. Be a mercenary. Build your crew. Become a legend. Coming soon.
Cyberpunk 2077 is an open-world, action-adventure role-playing game set in Night City, a dark future megalopolis obsessed with power, glamour, and body modification. Players take on the role of a cyber-enhanced mercenary named V, who faces the most powerful forces in the city in a fight for glory and survival. Created by the studio behind The Witcher series of games, Cyberpunk 2077 has reached a global audience since its launch in 2020, earning acclaim for its storytelling, gameplay, and the immersive nature of its open world.
This brand-new in-person experience, based on the world of Cyberpunk 2077, is built specifically for Zero Latency VR's untethered, free-roam technology. It will allow players to physically move together through a shared space, offering a new way to explore the world of Cyberpunk 2077. This will be a self-contained experience capturing the atmosphere and style of Night City beyond its original screen-based format, as seen in the original video game.
"Cyberpunk 2077 is one of the most richly imagined worlds in modern entertainment," said Tim Ruse, CEO of Zero Latency VR. "What makes this collaboration special is how naturally it aligns with what we do best. Zero Latency experiences are about freedom of movement and shared adrenaline, and Night City is a world that begs to be explored at a human scale. CD PROJEKT RED are experts in their craft, and we're looking forward to creating a new, unforgettable adventure."
Inspired by the world of Cyberpunk 2077, but not a direct translation of the video game, the experience will be developed specifically for Zero Latency VR's global network of venues, leveraging large-scale arenas, wireless headsets, and full-body movement to deliver a social, fully immersive VR adventure unlike anything currently available.
Additional details about the experience will be announced at a later date. The Cyberpunk 2077 immersive VR experience is set to launch at Zero Latency VR locations worldwide.
ABOUT ZERO LATENCY VR:
Zero Latency VR is the global pioneer in immersive entertainment, pushing the boundaries of what's possible in location-based experiences. As the largest free-roam VR network on the planet, with 150+ cutting-edge venues across 30 countries, Zero Latency is where thrill-seekers come to live out their wildest fantasies.
ABOUT CD PROJEKT RED:
CD PROJEKT RED is a video game development studio founded in 2002. Its flagship titles include the futuristic role-playing game Cyberpunk 2077 and its spy-thriller expansion Phantom Liberty, alongside The Witcher series of games including The Witcher 3: Wild Hunt and its two expansions. CD PROJEKT RED also created the award-winning Netflix anime series Cyberpunk: Edgerunners, set in the same universe as the game. CD PROJEKT RED is part of the CD PROJEKT Group. CD PROJEKT S.A. is listed on the Warsaw Stock Exchange (ISIN: PLOPTTC00011).
SOCIAL MEDIA LINKS:
Instagram and TikTok: @zerolatencyvr
LinkedIn: Zero Latency VR
Press Contact:
Luke Mitchell
PR & Communications Manager
+61 (0) 413614412
luke.mitchell@zerolatencyvr.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CD PROJEKT RED PARTNERS WITH ZERO LATENCY VR TO BRING THE WORLD OF CYBERPUNK 2077 INTO IMMERSIVE VR
